The Department of Health – Abu Dhabi (DoH) signed a landmark Memorandum of Understanding (MoU) with a set of global and local sector leaders to establish a collaborative framework that will shape the future of healthcare through precision medicine and advanced therapies.
The DoH’s partners in the new initiative are PureHealth, Khalifa University of technology (KU), Illumina, M42, Institute for Healthier Living Abu Dhabi (IHLAD) and New York University Abu Dhabi (NYUAD).
Abu Dhabi health alliance
The agreement, signed during Abu Dhabi Global Health Week 2025 (ADGHW), reflects a shared ambition aligned with DoH’s vision to establish one of the world’s most intelligent healthcare systems, driven by cutting-edge genomic science, AI-powered insights, and collaborative innovation.
The new systems are to be developed particularly in critical areas such as oncology, rare genetic diseases, and metabolic disorders.
Dr. Asma Al Mannaei, Executive Director – Health Life Sciences Sector at DoH, said Abu Dhabi is leading the transformation of health systems by harnessing science, technology, and genomics to build a future-ready model of care.
“Precision medicine represents a pivotal shift from a one-size-fits-all approach to deeply personalised, preventive, and proactive healthcare. Through such strategic partnerships, we are positioning the emirate as a global life sciences hub,” Al Mannaei said.
The multi-stakeholder collaboration will focus on establishing genomic infrastructure and population health programmes tailored to emirati and regional populations.
It will also focus on launching research and development initiatives in advanced therapeutics such as gene therapy and cell-based treatments and support the integration of precision medicine into clinical practice, through pharmacogenomics and genome testing.
Additionally, the partnership will build artificial intelligence (AI) and digital platforms for genomic data analysis and personalised patient care, as well as education and training pathways to develop local expertise in genomic and precision medicine.
Follow us on
